½ÃÀ庸°í¼
»óÇ°ÄÚµå
1590313
CDMO : ¼¼°è ½ÃÀå¿¡¼ÀÇ ±âȸ¿Í °æÀï ȯ°æGlobal Market Opportunities and Competitive Landscape for CDMO |
¼¼°è CDMO ½ÃÀå ±Ô¸ð´Â 2023³â 1,280¾ï ´Þ·¯, 2024³â 1,366¾ï ´Þ·¯¿¡¼ ¿¹Ãø ±â°£ µ¿¾È 7.0%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î 2029³â ¸»¿¡´Â 1,916¾ï ´Þ·¯ ±Ô¸ð·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Á¦¾à/¿ÏÁ¦Ç° Á¦Á¶ ¼ºñ½º ºÎ¹®Àº 2024³â 506¾ï ´Þ·¯¿¡¼ 2029³â ¸» 697¾ï ´Þ·¯·Î ¿¬Æò±Õ 6.6% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ºÐ¼® ½ÃÇè ¹× ±ÔÁ¦ Áö¿ø ¼ºñ½º ºÎ¹®Àº 2024³â 19.7¾ï ´Þ·¯¿¡¼ 2029³â ¸»¿¡´Â 299¾ï ´Þ·¯¿¡ À̸£¸ç, ¿¬Æò±Õ 8.7% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¼¼°è CDMO ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä, ½ÃÀå ¿µÇâ¿äÀÎ ¹× ½ÃÀå ±âȸ ºÐ¼®, ±ÔÁ¦ ȯ°æ, ½Å±â¼ú ¹× ±â¼ú °³¹ß µ¿Çâ, ½ÃÀå ±Ô¸ð ÃßÀÌ ¹× ¿¹Ãø, °¢Á¾ ºÎ¹®º°/Áö¿ªº° »ó¼¼ ºÐ¼®, °æÀï ±¸µµ, ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇص帳´Ï´Ù.
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
The global CDMO market for drug product/finished drug manufacturing services is expected to grow from $50.6 billion in 2024 to $69.7 billion by the end of 2029, at a CAGR of 6.6% from 2024 to 2029.
The global CDMO market for analytical testing and regulatory support services is expected to grow from $19.7 billion in 2024 to $29.9 billion by the end of 2029, at a CAGR of 8.7% from 2024 to 2029.
This report provides an overview of the pharmaceutical business and the function of contract development and manufacturing organizations (CDMOs). The analysis includes a review of the global CDMO market by service type, drug molecule type and end use. It also examines the regulatory policies, standards and inspection trends of the global CDMO markets. In addition, the competitive environment, significant rivals, significant leaders and top 10 manufacturers in the CDMO sector are also reviewed.
The report presents a detailed description of the service types (API manufacturing services, drug product/finished drug manufacturing service, pharmaceutical development services and analytical testing and regulatory support services) and current and historical market revenues. The CDMO markets are also segmented based on type of molecule (small-molecule drugs, biologics and advanced therapies) and end user (clinical and commercial). The market revenue for each geographic segment (North America, Europe, Asia-Pacific and the Rest of the World) has also been provided in the report.
In order to provide an in-depth understanding of the market, profiles of market participants, competitive landscape, key competitors and respective market share are also included in this report. For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029.